

# Information Disclosure Statement by Applicant (PTO/SB/O8)

Page 1 of 6

*Complete if Known*

Application No.:	09/772,445
Filing Date:	January 29, 2001
First Named Inventor:	KLEINMAN et al.
Group Art Unit:	1654
Examiner Name:	Ronald T. Niebauer
Attorney Docket No.:	2600-109
Customer No.:	6449
Confirmation No.:	1045

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1	4388234		Horecker	06-14-1983
	2	4543340		Goldstein et al.	09-24-1985
	3	5578570		Goldstein et al.	11-26-1996
	4	5593964		Goldstein et al.	01-14-1997
	5	5650145		Saint-Leger	07-22-1997
	6	5663071		Zetter et al.	09-02-1997
	7	6013279		Klett-Loch	01-11-2000
	8	6030948		Mann	02-29-2000
	9	6211155	B1	Dussourd et al.	04-03-2001
	10	6212946	B1	Naegele et al.	04-10-2001
	11	6272913	B1	Naegele et al.	08-14-2001
	12	6465421	B1	Duranton et al.	10-15-2002
	13	6586403	B1	Mathison et al.	07-01-2003
	14	6602519	B1	Stevenson et al.	08-05-2003
	15	6821524	B2	Marini	11-23-2004
	16	7268118	B2	Kleinman et al.	09-11-2007
	17	2003/0228266	A1	Marini	12-11-2003
	18	2004/0067227	A1	Goldstein	04-08-2004
	19	2004/0134282	A1	Hayashi et al.	07-15-2004

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.N./

# Information Disclosure Statement by Applicant (PTO/SB/O8)

<b>Information Disclosure Statement by Applicant (PTO/SB/O8)</b>		<i>Complete if Known</i>		
		Application No.:		09/772,445
		Filing Date:		January 29, 2001
		First Named Inventor:		KLEINMAN et al.
		Group Art Unit		1654
		Examiner Name:		Ronald T. Niebauer
		Attorney Docket No.:		2600-109
Customer No.:		6449		
Page 2 of 6		Confirmation No.:		
		1045		

	20	2007/0009469	A1	Kleinman et al.	01-11-2007
	21	2007/0111931	A9	Kleinman et al.	05-17-2007

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	22	DE	19711939	A1	Robert Bosch GmbH	09-24-1998	
	23	DE	19731420	A1	Robert Bosch GmbH	01-28-1999	
	24	EP	0124779	A2	George Washington Univ.	11-14-1984	
	25	EP	0229654	A2	Carl Richard Thornfeldt	07-22-1987	
	26	EP	0410348	A1	G.D. Searle & Co. Co.	01-30-1991	
	27	EP	0450240	A1	Gen-Ichiro Soma, et al.	10-09-1991	
	28	EP	0451903	A2	The Procter & Gamble Company	10-16-1991	
	29	FR	2530466	A1	Michel Hecmati	01-27-1984	AB
	30	JP	02-142717	A	Kanebo Ltd.	05-31-1990	AB
	31	JP	3-095120	A	Searle & Co.	04-19-1991	AB
	32	JP	5-507917	A		11-11-1993	AB
	33	JP	6-128295	A	Univ. Dandei	05-10-1994	AB
	34	JP	7-238037	A	Oreal	09-12-1995	AB
	35	JP	07-316022	A	Kyowa Hakko Kogyo Co. Ltd.	12-05-1995	AB
	36	JP	08-053326	A	Kanebo Ltd.	02-27-1996	AB
	37	JP	8-053329	A	Oreal	02-27-1996	AB

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.N./**

# Information Disclosure Statement by Applicant (PTO/SB/O8)

Page 3 of 6

<i>Complete if Known</i>	
<b>Application No.:</b>	09/772,445
<b>Filing Date:</b>	January 29, 2001
<b>First Named Inventor:</b>	KLEINMAN et al.
<b>Group Art Unit:</b>	1654
<b>Examiner Name:</b>	Ronald T. Niebauer
<b>Attorney Docket No.:</b>	2600-109
<b>Customer No.:</b>	6449
<b>Confirmation No.:</b> 1045	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	38	JP	60-142908	A	Kanebo Ltd.	07-29-1985	AB
	39	JP	62-215522	A	Kaar Richiyaado Soonfueruto	09-22-1987	AB
	40	JP	2001-526200	A		12-18-2001	AB
	41	RU	2295963	C1	Closed Joint Stock Company Scientific-Production Enterprise "Trinity"	03-27-2007	AB
	42	WO	84/03437	A1	Rudolf Trensch	09-13-1984	AB
	43	WO	92/00057	A1	Janssen Pharmaceutica N.V.	01-09-1992	
	44	WO	94/11499	A1	Max Planck Gesellschaft	05-26-1994	
	45	WO	94/18988	A2	Von Arnim	09-01-1994	
	46	WO	94/23739	A1	George Washington University	10-27-1994	
	47	WO	95/09646	A1	George Washington University	04-13-1995	
	48	WO	96/16983	A1	La Jolla Cancer Research Foundation	06-06-1996	
	49	WO	96/17584	A2	Maria Lore Klett-Loche	06-13-1996	AB
	50	WO	97/18239	A1	Rech de Pathologie Appl Soc D.	05-22-1997	AB
	51	WO	99/32072	A1	Morris Mann	07-01-1999	
	52	WO	00/06190	A1	The Government of the United States of America as represented by the Sec. of Health and Human Services, National Institutes of Health	02-10-2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.N./

# Information Disclosure Statement by Applicant (PTO/SB/O8)

Page 4 of 6

*Complete if Known*

**Application No.:** 09/772,445

**Filing Date:** January 29, 2001

**First Named Inventor:** KLEINMAN et al.

**Group Art Unit:** 1654

**Examiner Name:** Ronald T. Niebauer

**Attorney Docket No.:** 2600-109

**Customer No.:** 6449

**Confirmation No.:** 1045

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	53	"Anti-Aging FAQ," retrieved from <a href="http://www.aging-resource.org/faq.php">http://www.aging-resource.org/faq.php</a> , 2 pages, retrieved March 16, 2008.	
	54	AUDHYA et al.: "Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen," Proc. Natl. Acad. Sci. USA, vol. 81, no. 9, pp. 2847-2849, May 1984, Abstract Only.	
	55	"Causes of Wrinkling," retrieved from <a href="http://www.dermanetwork.org/glossary/2007/09/causes_of_wrinkling_1.html">http://www.dermanetwork.org/glossary/2007/09/causes_of_wrinkling_1.html</a> , 4 pages, retrieved March 16, 2008.	
	56	DARDENNE et al.: "Interactions Between Zinc and Thymulin," Metal-Based Drugs, vol. 1, no. 2-3, pp. 233-239, 1994, Abstract only.	
	57	"Doctor Secret Brand glycolic acid- Home chemical peel and skin beauty Glycolic Acid products," printed from <a href="http://www.doctorsecret.com">http://www.doctorsecret.com</a> , 4 pages, 2009.	
	58	ESTEVE: "An Active Complex for Prevention of Skin Aging," Drug & Cosmetic Industry, pp. 1-10, File Promt on STN, An No. 92:539512, Sept. 1994.	
	59	Fibrex Medical Inc.: "Fibrex Medical Initiates Phase II Trial of Treatment for Reperfusion Injury in Myocardial Infarction," printed from <a href="http://www.fibrexmedical.com/news_1.html">http://www.fibrexmedical.com/news_1.html</a> , 8 pages, 2007.	
	60	Fibrex Medical Inc.: "Technology – Mode of Action" printed from <a href="http://www.fibrexmedical.com/print/p_technology_2.html">http://www.fibrexmedical.com/print/p_technology_2.html</a> , 1 page, 2007.	
	61	Fibrex Medical Inc.: "Technology: Anti-Inflammatory Peptides," printed from <a href="http://www.fibrexmedical.com/print/p_technology_1.html">http://www.fibrexmedical.com/print/p_technology_1.html</a> , 2 pages, 2007.	
	62	Fibrex Medical Inc.: "Product Pipeline," printed from <a href="http://www.fibrexmedical.com/print/p_products_1.html">http://www.fibrexmedical.com/print/p_products_1.html</a> , 1 page, 2007.	
	63	Fibrex Medical Inc.: "Company Profile – About FIBREX Medical," printed from <a href="http://www.fibrexmedical.com/print/p_Index_2.html">http://www.fibrexmedical.com/print/p_Index_2.html</a> , 2 pages, 2007.	
	64	"FX06 Peptide for Myocardial Infarction Proves to be Safe, FIBREX Medical," printed from <a href="http://www.medicalnewstoday.com/printerfriendlynew.php?newsid=41250">http://www.medicalnewstoday.com/printerfriendlynew.php?newsid=41250</a> , 1 page, 2007.	
	65	GOLDSTEIN et al.: "Purification and Biological Activity of Thymosin, a Hormone of the Thymus Gland," Proceedings of the Natl. Acad. Sci., vol. 69, no. 7, pp. 1800-1803, July 1972.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.N./

# Information Disclosure Statement by Applicant (PTO/SB/O8)

*Complete if Known*

Application No.:	09/772,445
Filing Date:	January 29, 2001
First Named Inventor:	KLEINMAN et al.
Group Art Unit:	1654
Examiner Name:	Ronald T. Niebauer
Attorney Docket No.:	2600-109
Customer No.:	6449
Confirmation No.:	1045

Page 5 of 6

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	66	HAHN: "Thymuskin: Clinical Efficacy, Biological Effects, Modes of Action," 6 pages, July 2006.	
	67	Hannappel et al.: "Isolation Peptides from Calf Thymus," Biochem. And Biophys. Research Comm. Vol. 104, no. 1, pp. 266-271. Jan. 1982.	
	68	"How to Choose the Right at Home Chemical Peel," printed from <a href="http://www.articlesbase.com/skin-care-articles/how-to-choose-the-right-at-home-chemical-peel-85....">http://www.articlesbase.com/skin-care-articles/how-to-choose-the-right-at-home-chemical-peel-85....</a> , 4 pages, 2009.	
	69	IDS Health Inc :: Glandular Capsules :: LTP600 mg - 60 capsules printed from <a href="http://www.vitaminmegashop.com/product.php?productid=21340">http://www.vitaminmegashop.com/product.php?productid=21340</a> , 2 pages, 2010.	
	70	Integrative Therapeutics (60 capsules): Compare Prices, View Price History and Read Review... printed from <a href="http://www.nextag.com/integrative-therapeutics-thymucin-60-562833944/zzlzb4z23/prices.html">http://www.nextag.com/integrative-therapeutics-thymucin-60-562833944/zzlzb4z23/prices.html</a> , 2 pages, 2010.	
	71	Jackson: "Elderly and sun-affected skin: Distinguishing between changes caused by aging and changes caused by habitual exposure to sun," Canadian Family Physician, vol. 47, pp. 1236-1243, June 2001.	
	72	"Lamnин-511 Offers Hope for Regenerating Hair Follicles in Bald People," 4 pages, 2010.	
	73	LifeSciencesWorld: "Fibrex Medical Initiates Phase II Trial of Treatment for Reperfusion Injury in Myocardial Infarction," printed from <a href="http://www.lifesciencesworld.com/news/view/10639">http://www.lifesciencesworld.com/news/view/10639</a> , 3 pages. 2007.	
	74	LOW et al.: "Complete amino acid sequence of bovine thymosin $\beta_4$ : A thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations," Proc. Natl. Acad. Sci. USA, vol. 78, no. 2, pp. 1162-1166, February 1981.	
	75	LOW et al.: "Thymosin fraction 5 and 5A," Methods in Enzymology, vol. 116, pp. 219-233, 1985.	
	76	"New Study Confirms TB4 Improves Cardiovascular Function after Heart Attack," 2 pages, 2006.	
	77	"Obviate": definition of obviate by the Free Online Dictionary, Thesaurus and Encyclopedia, printed from <a href="http://www.thefreedictionary.com/obviate">http://www.thefreedictionary.com/obviate</a> , 3 pages, 2010.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.N./

# Information Disclosure Statement by Applicant (PTO/SB/O8)

		<i>Complete if Known</i>
		<b>Application No.:</b> 09/772,445
		<b>Filing Date:</b> January 29, 2001
		<b>First Named Inventor:</b> KLEINMAN et al.
		<b>Group Art Unit:</b> 1654
		<b>Examiner Name:</b> Ronald T. Niebauer
		<b>Attorney Docket No.:</b> 2600-109
		<b>Customer No.:</b> 6449
<b>Page 6 of 6</b>	<b>Confirmation No.:</b> 1045	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	78	PHILP et al.: "Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development." Mech Ageing Dev., vol. 125, no. 2, pp. 113-115, February 2004, Abstract Only.	
	79	RODRIGUES: "Do Anti-Wrinkle Creams Actually Work?" retrieved from <a href="http://www.buzzle.com/editorials/5-20-2006-96739.asp">http://www.buzzle.com/editorials/5-20-2006-96739.asp</a> , 3 pages, May 22, 2006.	
	80	Thymucin 60 Capsules printed from <a href="http://www.easyhealthzone.com/ProductDetails.asp?ProductCode=PP0077&amp;click-71">http://www.easyhealthzone.com/ProductDetails.asp?ProductCode=PP0077&amp;click-71</a> , 2 pages, 2010.	
	81	Thymucin (60) by Phytopharma - Phytopharma printed from <a href="http://www.phytostore.com/product/763948140060.html">http://www.phytostore.com/product/763948140060.html</a> , 2 pages, 2010.	
	82	ThymuSkin Hair Loss Products printed from <a href="http://www.thymusking.com/eshop/item.php?item=84&amp;cat=41">http://www.thymusking.com/eshop/item.php?item=84&amp;cat=41</a> , 1 page, 2010.	

Examiner Signature	/Ronald Niebauer/	Date Considered	01/03/2011
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.N./